Ismail Kola joins UCB as Executive Vice President, UCB & President of
UCB New Medicines(TM)
(Thomson Reuters ONE) - Brussels, Belgium, 10 November 2009 at 8:30 am CET - UCB todayannounced the appointment of Ismail Kola, Executive Vice President,UCB & President of UCB New Medicines(TM),UCB's discovery researchthrough to 'proof of concept' organization. Ismail Kola will joinUCB's Executive Committee with effect from November 23, 2009.Roch Doliveux, Chief Executive Officer of UCB said, "We are pleasedto announce Ismail's appointment to lead our internal and externaldiscovery of new medicines to treat patients with severe diseases.UCB is gaining a highly accomplished scientist with a track record ofsuccess in academia and the biopharma field. I am confident thatIsmail will make major leaps to the development of UCBNewMedicines(TM). His strong research and development background incombination with solid commercial understanding will move UCBNewMedicines(TM) beyond its current achievements to deliver UCB'sbreaktrough phase.''For more then 20 years, Ismail Kola has created a bridge between thescientific and academic worlds trough various projects funded byrenowned institutes such as the NHMRC (National Health & MedicalResearch Council) Australia, the National Institutes of Health, USAand Monash University in Australia. He has authored 159 technicalpublications in scientific and medical journals of the highestcaliber, and is a named inventor on 12 patents. Under his leadershipnumerous drugs have come to the market and many are now in late-stagedevelopment.Since March 2007, Dr. Kola has occupied the role of SeniorVice-President, Discovery Research and Early Clinical Research &Experimental Medicine, and Chief Scientific Officer atSchering-Plough. He came to Schering Plough from Merck where inJanuary 2003 he was appointed Senior Vice President/Site Head, BasicResearch. Prior to that, Ismail was Vice President, Research, andGlobal Head, Genomics Science and Biotechnology with PharmaciaCorporation, and served as a consultant to SmithKline BeechamPharmaceuticals where he was also a member of the Genomics AdvisoryBoard.As of 23 November 2009, UCB's Executive Committee, chaired by RochDoliveux, CEO, will have the following members, all of whom areExecutive Vice Presidents: Michele Antonelli, Fabrice Enderlin,Ismail Kola, Iris Loew-Friedrich, Mark McDade, Detlef Thielgen andBob Trainor.For further informationNancy Nackaerts, External Communications, UCBT +32.473.864.414, nancy.nackaerts(at)ucb.comAbout NewMedicines(TM)Encompassing discovery research activities through to proof ofconcept, UCB NewMedicines(TM) is an innovative and externallynetworked organisation established to secure the future pipeline anddeliver UCB's breakthrough products of the future.A disseminated research organisation will maximise UCB's investmentin scientific and medical breakthroughs via a highly collaborativeapproach to forming teams and projects to create new medicines. Basedon a 'hub' model of operation, UCB NewMedicines(TM) is located on twokey sites at Braine-l'Alleud, Belgium and Slough, UK. Operations atthese hubs focus on the therapeutic areas of CNS (Central NervousSystem) and Immunology with strong technology platforms underpinningthe research. The organisation houses leaders and experts who possessthe highest level skills to search, review, decide and transact onall aspects of the portfolio in all functions.Internal resources differentiate UCB whilst external resources areaccessed for routine activities or to provide specialistcomplementary skills and capabilities. The organisation fullyembraces external networking to support our focus on the pipelinedelivery and breakthrough science. Medics and patients informchoices from the outset of projects.About UCBUCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical companydedicated to the research, development and commercialization ofinnovative medicines with a focus on the fields of central nervoussystem and immunology disorders. Employing approximately 10 000people in over 40 countries, UCB generated revenue of 3.6 billioneuro in 2008. UCB is listed on Euronext Brussels (symbol: UCB).Forward looking statementThis press release contains forward-looking statements based oncurrent plans, estimates and beliefs of management. Such statementsare subject to risks and uncertainties that may cause actual resultsto be materially different from those that may be implied by suchforward-looking statements contained in this press release. Importantfactors that could result in such differences include: changes ingeneral economic, business and competitive conditions, effects offuture judicial decisions, changes in regulation, exchange ratefluctuations and hiring and retention of its employees.For the pdf-version of this press release, please click on the linkbelow:http://hugin.info/133973/R/1353778/327974.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 10.11.2009 - 08:31 Uhr
Sprache: Deutsch
News-ID 8149
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 450 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Ismail Kola joins UCB as Executive Vice President, UCB & President of
UCB New Medicines(TM)"
steht unter der journalistisch-redaktionellen Verantwortung von
UCB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
